Revenue
2021
2022
2023
2024
2025
Tenon Medical, Inc. (TNON)
Price$3.72Cached quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.9M | $3.3M | $2.9M | $691,000 | $160,000 |
| Gross profit | $2.4M | $1.7M | $1.2M | −$641,000 | $105,000 |
| Gross margin | 59.79% | 52.21% | 42.38% | −92.76% | 65.63% |
| Research & development | $2.1M | $2.6M | $3.2M | $2.8M | $1.7M |
| Operating expenses | $15.2M | $15.5M | $17.0M | $18.1M | $6.6M |
| Operating income | −$12.8M | −$13.8M | −$15.7M | −$18.7M | −$6.5M |
| Operating margin | −324.34% | −420.08% | −537.12% | −2,709.84% | −4,038.13% |
| EBITDA | −$12.5M | −$13.4M | −$15.5M | −$18.6M | −$6.5M |
| EBITDA margin | −317.70% | −407.63% | −530.33% | −2,698.55% | −4,036.88% |
| Net income | −$12.6M | −$13.7M | −$15.6M | −$18.9M | −$7.0M |
| Net profit margin | −318.36% | −417.24% | −532.14% | −2,737.63% | −4,405.00% |
| Basic EPSper basic share | -$59.50 | -$394.10 | -$2,402.40 | -$6,613.60 | -$21,868.00 |
| Diluted EPSper diluted share | -$59.50 | -$394.10 | -$2,402.40 | -$6,613.60 | -$21,868.00 |
Owners
Reported shareholders
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 14, 2025Form 4 | FOSTER STEVEN MCEO and President | BuyCommon stock | 19.5K | — | — | 22.9K |
| Nov 14, 2025Form 4 | FOSTER STEVEN MCEO and President | BuyCommon Stock Purchase Warrant · derivative | 19.5K | — | — | 19.5K |
| Nov 14, 2025Form 4 | Geist Wyatt D.Chief Innovation Officer | BuyCommon stock | 19.5K | — | — | 157.6K |
| Nov 14, 2025Form 4 | Geist Wyatt D.Chief Innovation Officer | BuyCommon Stock Purchase Warrant · derivative | 19.5K | — | — | 19.5K |
| Nov 14, 2025Form 4 | Grawey Nathaniel A.Chief Commercial Officer | BuyCommon stock | 101.2K | — | — | 239.3K |